ClinicalTrials.gg
CompletedNCT05965700Updated Nov 9, 2026

NVG-291 in Spinal Cord Injury Subjects

A Phase 1/2 interventional study of NVG-291 and Placebo Injection in Spinal Cord Injuries, Chronic Spinal Cord Injury and Subacute Spinal Cord Injury, sponsored by NervGen Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by NervGen Pharma · Phase 1/2, Interventional, and Treatment

Updated Oct 1, 2026Eligibility revisedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 968 studies in Spinal Cord Injuries with a site in United States — 250 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Enrollment
399th of 836
24 · median 24
Started
2023
with 56 others
Phase 1/2
31 of 968
9 open now
Registered
775th of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 399th largest by enrollment of the 836 interventional ones that give a count, is one of 57 that started in 2023, is one of 31 in phase 1/2, and was the 775th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

250 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

245 more — sign in →

All 250 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 375 Spinal Cord Injuries studies recruiting now, 166 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Read the detailed description

To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures. NOTE: Enrollment of the chronic cohort has been completed; approximately 20 individuals will be enrolled in the subacute group. For more information about the trial please visit www.connectscistudy.com.

03

Conditions studied

  • Spinal Cord Injuries
  • Chronic Spinal Cord Injury
  • Subacute Spinal Cord Injury

Keywords

  • Spinal Cord Injury
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject must provide written in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent.
  • Cervical spinal cord injury (SCI) resulting from acute physical trauma.
  • Males and females.
  • Age 18 to 75 years, inclusive.
  • Cervical SCI, incomplete, with a neurological level of injury at C7 or higher.
  • Had incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic Cohort 1) OR within 20 days to 90 days inclusive (Subacute Cohort 2) at time of randomization.
  • Chronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support).
  • Must have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows:
  • Chronic Cohort 1: Less than or equal to Level 14.
  • Subacute Cohort 2: Less than or equal to Level 10.
  • Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
  • Chronic Cohort 1:
  • Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity.
  • Must have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
  • Subacute Cohort 2:
  • Must have some voluntary (nonzero) force measured by grip dynamometry in at least one upper extremity.
  • Must have no more than one Prehension Ability grasp pattern score = 3 in at least one upper extremity.
  • Must not have a Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
  • Presence of Motor Evoked Potentials (MEPs):
  • Chronic Cohort 1: In two specific target muscle groups.
  • Subacute Cohort 2: In one specific target muscle group.
  • Must be fluent in English.
  • Must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Nontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, , radiation injury, surgical complications, or other disease process).
  • SCI due to gunshot wound or penetrating injury.
  • Two or more (noncontiguous) spinal cord lesions.
  • MRI or CT evidence of anatomically complete spinal cord transection.
  • Any form of ventilatory dependence.
  • Any condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation.
  • History of uncontrolled seizures, or:
  • Chronic Cohort 1: Any seizure within the last 6 months.
  • Subacute Cohort 2: Any seizure occurring 1 week or more after the SCI.
  • Metal implant in the head that is likely to interfere with MRI analysis.
  • Pregnant or breastfeeding.
  • Any neurological condition that is considered to interfere with performance or likely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia.
  • History of substance abuse within 12 months prior to screening, based on medical records or self-report.
  • Evidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma.
  • Prior treatment with cell therapy delivered into the central nervous system (intrathecal or intraparenchymal).
  • Severe neuropathic pain inadequately controlled by medication.
  • (BMI) > 40 kg/m2.
  • Received botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months.
  • Received 4-aminopyridine within 7 days of first dose.
  • Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide.
  • Intrathecal opioid use.
  • Currently participating in an interventional clinical trial.
  • Received a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization.
  • Receiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent or within 4 weeks of randomization, whichever is longer.
  • Any implanted internal spinal cord stimulator.
  • Currently receiving neuromuscular stimulation.
  • Currently receiving vagal or phrenic nerve stimulation.
  • Chronic Cohort 1 only: Any to baseline and on-study MRIs, such as:
  • History of a cardiac pacemaker or pacemaker wires.
  • Ferromagnetic metallic particles in the body.
  • Baclofen pump.
  • Vascular clips in the head.
  • Prosthetic heart valves.
  • Severe claustrophobia impeding ability to participate in an imaging study.
  • Malignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ.
  • History of medically significant hepatic disease or evidence of impaired liver function based on initial laboratory testing.
  • Severe renal insufficiency, defined as \< 30 mL/min/1.73m2.
  • Any disease, concomitant injury (such as significant traumatic brain injury), or condition that could interfere with the performance or interpretation of the protocol-specified assessments, in the opinion of the investigator.
  • Any other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    NVG-291 for SC Injection

    NVG-291 administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.

    Drug: NVG-291

  • Placebo comparator
    Placebo for SC Injection

    Matching placebo administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.

    Drug: Placebo Injection

Interventions

  • A once daily injection

  • DrugPlacebo Injection

    A once daily injection

06

What researchers measure

Primary outcomes

  1. Electrophysiological

    MEP amplitudes (corticospinal contribution) in key target muscle groups

    Time frame: 12 weeks

Secondary outcomes

  1. 10mWT time

    Walking speed

    Time frame: 12 weeks

  2. 9-HPT time

    Upper extremity dexterity

    Time frame: 12 weeks

  3. Dynamometry testing (pinch grip, Chronic cohort 1; hand grip, Subacute cohort 2)

    Recorded force

    Time frame: 12 weeks

  4. Graded and Redefined Assessment of Strength, Sensibility, and Prehension Test

    Hand function Max Score 116 points

    Time frame: 12 weeks

  5. Lower extremity motor score (LEMS)

    Lower extremity Max Score 50 points

    Time frame: 12 weeks

  6. Upper extremity motor score (UEMS)

    Upper extremity Max Score 50 points

    Time frame: 12 weeks

  7. Incidences of Treatment Emergent Adverse Events (Safety and Tolerability)

    incidences of treatment emergent adverse events

    Time frame: 16 Weeks

  8. Plasma Concentration of Study Drug

    initial and steady state predose and peak plasma drug concentrations

    Time frame: 12 Weeks

07

Study locations

1 site
  • Shirley Ryan AbilityLab
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Hosseini SM, Stecina K, Nemati S, Wang RR, Zhang JV, Karimi-Abdolrezaee S. Circuit Reconstruction after Traumatic Spinal Cord Injury by Cellular and Pharmacological Approaches. J Neurosci. 2025 Aug 27;45(35):e0362252025. doi: 10.1523/JNEUROSCI.0362-25.2025. PubMed 40744729 ↗

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Dec 2025, 28 months.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2023
First posted
Jul 28, 2023
StartActual
Aug 8, 2023
Primary completionActual
Dec 31, 2025
CompletionActual
Jan 21, 2026
Results delay requested
Sep 24, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
15 inclusion criteria edited, 1 added; 16 exclusion criteria edited, 3 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedCervical spinal cord injury (SCI) resulting from acute physical trauma.
  • EditedAge 18 -to 75 years, inclusive.
  • EditedCervical SCI, incomplete, with a neurological level of injury being at C7 or higher.
  • EditedChronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support). (Cohort 1 only)
  • EditedFor Chronic cohortCohort 1: Less than or equal to Level 14.
  • EditedFor Subacute cohortCohort 2: Less than or equal to Level 10.
  • ChangedBefore GRASSP/hand grip strength Prehension Ability scoreNow Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
  • EditedFor Chronic cohortCohort 1:
  • EditedMust have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion i
  • AddedMust have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
  • EditedFor Subacute cohortCohort 2:
  • EditedMust have no more than one Prehension Ability grasp patternspattern score = 3 in at least one upper extremity.
  • EditedMust not have a Prehension Ability grasp patternspattern score = 4 in the upper extremity satisfying the criterion above.
  • EditedChronic Cohort 1: In two specific target muscle groups (Cohort 1).
  • EditedSubacute Cohort 2: In one specific target muscle group (Cohort 2).
  • EditedSubjects mustMust be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.
Exclusion criteria
  • EditedSpinal cord injurySCI due to gunshot wound or penetrating injury.
  • EditedAny condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation.
  • RemovedHistory of uncontrolled seizures or any seizure within the last 6 months (Cohort 1). History of uncontrolled seizures, or any seizure occurring 1 week or more after the SCI (Cohort 2)
  • AddedHistory of uncontrolled seizures, or:
  • AddedChronic Cohort 1: Any seizure within the last 6 months.
  • AddedSubacute Cohort 2: Any seizure occurring 1 week or more after the SCI.
  • EditedPregnant or breast feedingbreastfeeding.
  • EditedAny neurological condition that is considered to interfere with performance or liklylikely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia.
  • EditedEvidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma.
  • EditedPrior treatment with cell therapy delivered into the CNScentral nervous system (intrathecal or intraparenchymal).
  • EditedBody mass index (BMI) > 40 (body weight in kilograms divided by height in meters squared)kg/m2.
  • EditedReceiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent to participate in this study or within 4 weeks of randomization, whichever is longer.
  • EditedChronic cohortCohort 1 only: Any contraindication to undergo baseline and on -study MRIs, such as:
  • EditedHistory of a cardiac pacemaker or pacemaker wires, OR.
  • EditedFerromagnetic metallic particles in the body, OR.
  • EditedBaclofen pump, OR.
  • EditedVascular clips in the head, OR.
  • EditedProsthetic heart valves, OR.
  • EditedSevere renal insufficiency, as defined byas eGFR < 30 mL/min/1.73m2.
  • EditedAny disease, concomitant injury, (such as significant traumatic brain injury), or other condition that could interfere with the performance or interpretation of the protocol -specified assessments, in the opinion of the investigator.
Oct 1, 2026
Interventions
Added Drug: Placebo Injection. Arm changed NVG-291 for Injection→NVG-291 for SC Injection; Placebo→Placebo for SC Injection
Oct 1, 2026
Show all 3 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 1, 2026
    Eligibility 15 inclusion criteria edited, 1 added; 16 exclusion criteria edited, 3 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedCervical spinal cord injury (SCI) resulting from acute physical trauma.
    • EditedAge 18 -to 75 years, inclusive.
    • EditedCervical SCI, incomplete, with a neurological level of injury being at C7 or higher.
    • EditedChronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support). (Cohort 1 only)
    • EditedFor Chronic cohortCohort 1: Less than or equal to Level 14.
    • EditedFor Subacute cohortCohort 2: Less than or equal to Level 10.
    • ChangedBefore GRASSP/hand grip strength Prehension Ability scoreNow Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
    • EditedFor Chronic cohortCohort 1:
    • EditedMust have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion i
    • AddedMust have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
    • EditedFor Subacute cohortCohort 2:
    • EditedMust have no more than one Prehension Ability grasp patternspattern score = 3 in at least one upper extremity.
    • EditedMust not have a Prehension Ability grasp patternspattern score = 4 in the upper extremity satisfying the criterion above.
    • EditedChronic Cohort 1: In two specific target muscle groups (Cohort 1).
    • EditedSubacute Cohort 2: In one specific target muscle group (Cohort 2).
    • EditedSubjects mustMust be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.
    Exclusion criteria
    • EditedSpinal cord injurySCI due to gunshot wound or penetrating injury.
    • EditedAny condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation.
    • RemovedHistory of uncontrolled seizures or any seizure within the last 6 months (Cohort 1). History of uncontrolled seizures, or any seizure occurring 1 week or more after the SCI (Cohort 2)
    • AddedHistory of uncontrolled seizures, or:
    • AddedChronic Cohort 1: Any seizure within the last 6 months.
    • AddedSubacute Cohort 2: Any seizure occurring 1 week or more after the SCI.
    • EditedPregnant or breast feedingbreastfeeding.
    • EditedAny neurological condition that is considered to interfere with performance or liklylikely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia.
    • EditedEvidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma.
    • EditedPrior treatment with cell therapy delivered into the CNScentral nervous system (intrathecal or intraparenchymal).
    • EditedBody mass index (BMI) > 40 (body weight in kilograms divided by height in meters squared)kg/m2.
    • EditedReceiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent to participate in this study or within 4 weeks of randomization, whichever is longer.
    • EditedChronic cohortCohort 1 only: Any contraindication to undergo baseline and on -study MRIs, such as:
    • EditedHistory of a cardiac pacemaker or pacemaker wires, OR.
    • EditedFerromagnetic metallic particles in the body, OR.
    • EditedBaclofen pump, OR.
    • EditedVascular clips in the head, OR.
    • EditedProsthetic heart valves, OR.
    • EditedSevere renal insufficiency, as defined byas eGFR < 30 mL/min/1.73m2.
    • EditedAny disease, concomitant injury, (such as significant traumatic brain injury), or other condition that could interfere with the performance or interpretation of the protocol -specified assessments, in the opinion of the investigator.
    Interventions Added Drug: Placebo Injection. Arm changed NVG-291 for Injection→NVG-291 for SC Injection; Placebo→Placebo for SC Injection
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05965700
Lead sponsor
NervGen Pharma
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Aug 8, 2023
Primary completion
Dec 31, 2025
Completion
Jan 21, 2026
Last update
Nov 9, 2026

Study contacts

Randall Kaye, M.D.
study director · NervGen Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVG-291

Start the discussion